{"id":"fimasartan-and-rosuvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL1951143","moleculeType":"Small molecule","molecularWeight":"501.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a fixed-dose combination where fimasartan acts as an angiotensin II receptor blocker (ARB) to reduce vasoconstriction and lower blood pressure, and rosuvastatin is a statin that inhibits the rate-limiting enzyme in cholesterol biosynthesis to reduce LDL cholesterol levels. Together, they provide complementary cardiovascular protection by addressing both hypertension and dyslipidemia.","oneSentence":"Fimasartan blocks angiotensin II receptors to lower blood pressure, while rosuvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:36.428Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension with dyslipidemia"},{"name":"Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy"}]},"trialDetails":[{"nctId":"NCT02913794","phase":"","title":"Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-10-11","conditions":"Cardiovascular Diseases, Hyperlipidemias","enrollment":541},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT03156842","phase":"PHASE3","title":"Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-05-29","conditions":"Essential Hypertension, Dyslipidemia","enrollment":138},{"nctId":"NCT02704702","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-03","conditions":"Hypertension","enrollment":36},{"nctId":"NCT02378064","phase":"PHASE4","title":"Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation","status":"COMPLETED","sponsor":"CHEOL WHAN LEE, M.D., Ph.D","startDate":"2015-05","conditions":"Inflammation Plaque, Atherosclerotic, Coronary Disease, Renin-Angiotensin System","enrollment":50},{"nctId":"NCT02995720","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-08-26","conditions":"Hypertension, Hyperlipidemia","enrollment":60},{"nctId":"NCT02166814","phase":"PHASE3","title":"A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2014-08","conditions":"Essential Hypertension, Dyslipidemia","enrollment":140},{"nctId":"NCT02569814","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-09","conditions":"Hypertension, Hyperlipidemia","enrollment":100},{"nctId":"NCT02397538","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-02","conditions":"Hypertension","enrollment":50},{"nctId":"NCT02205190","phase":"PHASE1","title":"to Compare the Pharmacokinetics and Safety of Fimasartan/Rosuvastatin Combination Tablet and Coadministration of Fimasartan and Rosuvastatin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2014-07","conditions":"Hypertension","enrollment":81},{"nctId":"NCT01921946","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2013-08","conditions":"Hypertension","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fimasartan and Rosuvastatin","genericName":"Fimasartan and Rosuvastatin","companyName":"Boryung Pharmaceutical Co., Ltd","companyId":"boryung-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fimasartan blocks angiotensin II receptors to lower blood pressure, while rosuvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis. Used for Hypertension with dyslipidemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}